RESCUE-II Study Results Demonstrate Safety and Feasibility of the BASHIR™ Endovascular Catheter (BEC) in Treating Pulmonary Embolism (PE) On-The-Table (OTT)
New Britain, PA June 25, 2025 --( PR.com )-- NeThrombolex, Inc., a medical device manufacturer committed to advancing solutions for the treatment of arterial and venous thromboembolic diseases, announced the publication of the results from the RESCUE-II Study in JACC: Advances. The RESCUE-II Study was a single-center, prospective study evaluating the safety and feasibility of OTT pharmaco-mechanical lysis (PML) without postprocedural infusion when treating patients with acute intermediate-risk PE. 9 patients were enrolled and successfully treated with low dose r-tPA (4mg per pulmonary artery) using the BEC. At 48 hours, the mean RV/LV ratio decreased by 22.3%, and pulmonary artery obstruction, as measured by the Refined Modified Miller Index, was reduced by 29.2%. There were no major bleeding events, no deaths or serious adverse events through 30-day follow-up.
'This marks a significant milestone for our Company, as we are proud to contribute high quality evidence to the field and remain committed to advancing innovative treatments.' said Michael Cerminaro, President & CEO of Thrombolex. 'We would like to thank Senator Steve Santarsiero and the Department of Community and Economic Development of the Commonwealth of PA for their grant funding support of this important clinical research.'
'The RESCUE-II Study demonstrated encouraging safety and feasibility, while reinforcing the clinical value of this novel OTT protocol,' said, Dr. Vlad Lakhter, IC at Temple University Hospital. 'These results warrant further investigation in larger, multicenter trials like the RAPID-PE Study, which is currently enrolling patients.'
An independent data safety monitoring board adjudicated all clinical events for the RESCUE-II Study, while imaging data was assessed by an independent Core laboratory.
The publication is available online in JACC: Advances: https://www.sciencedirect.com/science/article/pii/S2772963X25002078
About Thrombolex, Inc.
Founded in 2016, Thrombolex is engaged in the design, development, and distribution of innovative endovascular catheters used in interventional procedures, particularly in pharmaco-mechanical lysis (PML) in patients who suffer from arterial and venous thromboembolic conditions. The Company is currently marketing eight (8) different FDA-cleared devices that are all based on the BASHIR™ Endovascular Catheter platform technology. For general inquiries, please contact Thrombolex at [email protected] or for more information about Thrombolex and its solutions, visit www.thrombolex.com.
Contact Information:
Thrombolex, Inc.
Tony Litwiller
(704) 408-0927
Contact via Email
www.Thrombolex.com
Read the full story here: RESCUE-II Study Results Demonstrate Safety and Feasibility of the BASHIR™ Endovascular Catheter (BEC) in Treating Pulmonary Embolism (PE) On-The-Table (OTT)
Press Release Distributed by PR.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
31 minutes ago
- Yahoo
Dyne Therapeutics Announces Pricing of $200.0 Million Public Offering of Common Stock
WALTHAM, Mass., June 30, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced the pricing of an underwritten public offering of 24,242,425 shares of its common stock at a public offering price of $8.25 per share. The gross proceeds to Dyne from the offering, before deducting underwriting discounts and commissions and offering expenses payable by Dyne, are expected to be $200.0 million. All shares in the offering are being sold by Dyne. The offering is expected to close on or about July 2, 2025, subject to customary closing conditions. In addition, Dyne has granted the underwriters a 30-day option to purchase up to an additional 3,636,363 shares of its common stock at the public offering price, less the underwriting discounts and commissions. Morgan Stanley, Jefferies, Stifel and Guggenheim Securities are acting as joint book-running managers for the offering. Jones is acting as co-manager for the offering. The offering is being made pursuant to a shelf registration statement on Form S-3 that was previously filed with the Securities and Exchange Commission ('SEC') on March 5, 2024 and became automatically effective upon filing. This offering is being made only by means of a prospectus supplement and accompanying prospectus that form a part of the registration statement. A preliminary prospectus supplement relating to and describing the terms of the offering has been filed with the SEC and may be obtained for free by visiting the SEC's website at A final prospectus supplement relating to the offering will be filed with the SEC. When available, copies of the final prospectus supplement and the accompanying prospectus may also be obtained by contacting: Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, NY 10014, or by email at prospectus@ Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, New York, NY 10022, by telephone at (877) 821-7388, or by email at Prospectus_Department@ Stifel, Nicolaus & Company, Incorporated, Attention: Prospectus Department, One Montgomery Street, Suite 3700, San Francisco, CA 94104, by telephone at (415) 364-2720 or by email at syndprospectus@ or Guggenheim Securities, LLC, Attention: Equity Syndicate Department, 330 Madison Avenue, 8th Floor, New York, NY 10017, by telephone at (212) 518-9544, or by email at GSEquityProspectusDelivery@ This press release shall not constitute an offer to sell, or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. About Dyne Therapeutics Dyne Therapeutics is focused on delivering functional improvement for people living with genetically driven neuromuscular diseases. We are developing therapeutics that target muscle and the central nervous system (CNS) to address the root cause of disease. The company is advancing clinical programs for myotonic dystrophy type 1 (DM1) and Duchenne muscular dystrophy (DMD), and preclinical programs for facioscapulohumeral muscular dystrophy (FSHD) and Pompe disease. Forward-Looking Statements This press release contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this press release, including statements relating to the anticipated closing date of the public offering, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. The words 'anticipate,' 'believe,' 'continue,' 'could,' 'estimate,' 'expect,' 'intend,' 'may,' 'might,' 'objective,' 'ongoing,' 'plan,' 'predict,' 'project,' 'potential,' 'should,' or 'would,' or the negative of these terms, or other comparable terminology are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Dyne may not actually achieve the plans, intentions or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements as a result of various important factors, including the risks and uncertainties related to the satisfaction of customary closing conditions for the public offering and other factors discussed in the 'Risk Factors' section of the preliminary prospectus supplement filed with the SEC on June 30, 2025, as well as the risks and uncertainties identified in Dyne's filings with the SEC, including Dyne's most recent Form 10-Q and in subsequent filings Dyne may make with the SEC. In addition, the forward-looking statements included in this press release represent Dyne's views as of the date of this press release. Dyne anticipates that subsequent events and developments will cause its views to change. However, while Dyne may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Dyne's views as of any date subsequent to the date of this press release. Contacts: Investors Mia Tobiasir@ Media Stacy Nartkersnartker@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
CBS News
31 minutes ago
- CBS News
North Carolina family fears Medicaid cuts would force them to ration treatments for 6-year-old
Kennedy Beaver has been going to therapy sessions at least twice a week after she was diagnosed with Noonan syndrome, a genetic condition that stunts development. The 6-year-old from North Carolina is among 600,000 people in the state who could lose access to healthcare as Congress is poised to approve major cuts to Medicaid funding proposed in President Trump's so-called "big, beautiful bill," according to according to the state's Medicaid office. "For her, that's short stature, poor growth, low muscle tone," her mother, Marilyn, described Kennedy's condition in an interview with CBS News. "So with that, we became eligible for something called the CAP/C waiver through Medicaid." 6-year-old Kennedy Beaver CBS News North Carolina's Community Alternatives Program for Children pays for most of the treatments and medications for patients younger than 20 who have significant medical needs. If the Beavers didn't have CAP/C, the family says they would be paying over $4,000 a month for treatments and medications — even with private health insurance coverage. "This is our medication that, without the Medicaid coverage, would be $3,200 a month, because our primary insurance has denied us," Marilyn said. The family says they also fear that if the proposal on Capitol Hill becomes law, they may have to go back to rationing Kennedy's treatment. North Carolina Medicaid Deputy Secretary Jay Ludlam says the cut that's being proposed at the federal level will "at some point affect the entire program." The state's Medicaid program oversees more than 3 million people who currently receive the healthcare benefits. State officials say if federal funding falls short, the CAP/C program could be on the chopping block. "When you take $700 billion out of Medicaid nationally ... there's no way to really do that without people losing coverage, without having to change the benefits and the coverage that people get," Ludlam said. When asked what she would tell lawmakers in Congress if she had the opportunity to speak with them, Marilyn said they should make changes without cutting services. "It's fixing the healthcare system so that everyone in the country can get a level of care that meets their needs," she said.
Yahoo
32 minutes ago
- Yahoo
The most surprising victim of Trump's terrible tax agenda
The Republican Party's saving grace is supposed to be its commitment to economic growth and consumer abundance. Sure, the GOP may see unemployed cancer patients as shiftless mooches — and the Lorax as literature's greatest villain — but for precisely those reasons, Republicans are allegedly able stewards of industrial development: Unconstrained by concerns about inequality, the environment, or social justice, the GOP will unleash the private sector's productive potential. Republicans won't balance Americans' hunger for cheap gasoline against their enlightened interest in cleaner air or a cooler planet — they'll get you the cheap fuel now. And they won't weigh America's stake in technological supremacy against the risks of unregulated innovation — they'll give cutting-edge companies whatever they need to achieve global dominance. At least, this is the impression that Republicans have tried to cultivate, and which voters largely bought last November. According to polling by Democratic data firm Blue Rose Research, Americans in 2024 believed that the GOP would be better than Democrats on the economy and cost of living — but worse on income inequality and the environment — and considered the former issues more important. But the GOP's priorities aren't as advertised. President Donald Trump's agenda does not ask Americans to accept a dirtier atmosphere and more inegalitarian social order in exchange for cheaper goods, faster technological progress, and national industrial dominance. Rather, it asks us to accept not only greater inequality and environmental degradation, but also, higher prices, slower technological progress, and worse industrial performance for the sake of…I'm not sure what. Perhaps the conservative movement's cultural grievances? Or Trump's odd ideological fixations? In any case, Trump has long made his disregard for affordability and economic growth plain. As of mid-June, Trump's tariffs were still poised to increase Americans' annual cost of living by $2,000 on average, while knocking 0.6 percent off of economic growth. His administration's assault on funding for scientific research, meanwhile, has undermined US tech companies. And his crackdown on immigration is both chasing top-tier talent out of the US and exacerbating labor shortages in the construction industry, thereby slowing the pace of housing and infrastructure development. Now, with his inaptly named One Big Beautiful Bill (BBB) — which is poised to clear the Senate this week — Trump is rounding out his 'worst of both worlds' agenda. Predictably, his tax cut package would exacerbate inequality, taking health care and food assistance away from poor people in order to shower tax breaks on the wealthy. And the legislation also evinces contempt for the environment, offering new subsidies to American coal producers. More remarkably, however, BBB would also increase electricity prices for consumers while undermining America's competitiveness in a range of critical sectors. Specifically, the latest version of Trump's bill aims to throttle the production of renewable energy in the US. The legislation not only phases out federal subsidies for wind and solar power by 2027, but also imposes a new excise tax on renewable projects that use inputs made in China. Since Chinese firms dominate green energy supply chains, a very high percentage of all wind and solar development in the United States would be adversely impacted by the tax. What's more, Trump's legislation would actually reinforce American green energy companies' dependence on Chinese suppliers by curtailing subsidies to domestic manufacturers of solar panels, wind turbines, and batteries. (As of this writing, some Republican senators are pushing an amendment that would strike the excise tax from the bill. But that amendment's fate is unclear. And even if it is adopted, Trump's legislation would still curtail subsidies to the solar and wind industries.) Taken together, these measures could slash the amount of new clean energy capacity added to America's grid over the next 10 years by more than 72 percent, according to an analysis from the Rhodium Group. That scarcity will translate into higher electricity costs for consumers. According to a variety of recent studies, merely ending federal tax credits for wind and solar could push up the average family's energy bill by as much as $400 per year within a decade. While increasing US households' costs, Trump's bill also reduces American firms' competitiveness in some of the world's fastest-growing industries. On one level, this is obvious. Renewables accounted for more than 90 percent of all newly added electricity generation last year. Even if America clings tightly to fossil fuels, demand for wind and solar energy is going to surge worldwide in the coming decades. If the United States actively sabotages its clean power industry, it will cede a larger share of the global energy market to China and other rival nations. Less intuitively, the BBB also undermines America's artificial intelligence industry. AI companies need vast amounts of new electricity to power their data centers. And renewables are uniquely well-suited to provide such power. At present, utilities can build wind and solar much faster than new natural gas plants, as there is a years-long backlog in the global market for natural gas turbines. Likewise, nuclear energy takes an enormous amount of time and regulatory wrangling to expand. Thus, if the federal government makes building renewables slower and more expensive, then American AI firms' progress could also be stymied. This has led some in the tech industry to criticize the bill. 'We urge the Senate to prioritize a reliable and resilient energy mix that advances AI innovation and growth and reject provisions that will harm the U.S.'s ability to compete in the global race for AI and energy dominance,' Janae Washington, a spokesperson for the Information Technology Industry Council, told the Washington Post on Sunday. Elon Musk, meanwhile, declared Saturday that 'The latest Senate draft bill will destroy millions of jobs in America and cause immense strategic harm to our country! Utterly insane and destructive. It gives handouts to industries of the past while severely damaging industries of the future.' Even one of the bill's strongest proponents — the pro-fossil fuels advocate Alex Epstein — has lamented its new tax on renewables with Chinese inputs, as has the US Chamber of Commerce. Nevertheless, as of this writing, that tax remains in the legislation. It is therefore a mistake to see Trump's agenda as prioritizing innovation over equality or affordability over the environment. The BBB doesn't concentrate wealth or degrade the climate in pursuit of some higher objective. Rather, it treats increasing inequality and boosting carbon emissions as ends in themselves — goals that it is prepared to pursue even at great cost to America industrial competitiveness and living standards.
